Type I-Fv and engineered type IV-A1 CRISPR–Cas effectors facilitate genome reduction in Escherichia coli
Nucleic Acids Research · 26.11.2025 · 53 (22)
DOI: 10.1093/nar/gkaf1399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 18.12.2025. Verfasst von Nathalie Klein und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Philipps-Universität Marburg, Hans-Meerwein-Straße 6, 35043 Marburg, Germany. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Escherichia coli, Gene Editing, Genome, Bacterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, DFG, Microcosm Earth Center.
Abstract (Originalsprache)
Class 1 CRISPR–Cas systems utilize multi-subunit effector ribonucleoprotein complexes to identify and target DNA. Upon recognition, type I systems recruit the helicase/nuclease Cas3 for DNA degradation, while type IV-A systems use the helicase CasDinG for transcriptional repression. Here, we developed two recombinant class 1 CRISPR–Cas genome editing tools for inducing large genomic deletions: the compact type I-Fv (also termed I-F2) system from Shewanella putrefaciens and the type IV-A1 system from Pseudomonas oleovorans. In the latter, CasDinG was engineered to include a C-terminal HNH nuclease domain, conferring DNA cleavage activity and enabling analysis of CasDinG processivity. Whole-genome sequencing of Escherichia coli BL21-AI was used to monitor genome reduction and DNA repair mechanisms in response to CRISPR–Cas-induced damage. Small deletions were flanked by microhomologies, consistent with repair via alternative end joining, whereas deletions larger than 10 kb consistently terminated at nearby IS1 elements, implicating these sequences in the repair process. This study introduces compact type I and engineered type IV-A genome editing tools with distinct protospacer-adjacent motif requirements and provides new insights into CasDinG evolution and the DNA repair pathways engaged during CRISPR–Cas-mediated genome editing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biology, Philipps-Universität Marburg, Hans-Meerwein-Straße 6, 35043 Marburg, Germany.
- Helmholtz Institute for RNA-based Infection Research (HIRI-HZI), Josef-Schneider-Straße 2, 97080 Würzburg, Germany.
- Department of Biochemistry III, University of Regensburg, Universitätsstraße 31, 93053 Regensburg, Germany.
- Center for Synthetic Microbiology (SYNMIKRO), Karl-von-Frisch-Straße 14, 35043 Marburg, Germany.
ORCID-Profile: Lennart Randau
Förderung
- German Research Foundation
- DFG
- Microcosm Earth Center
- Helmholtz Association
- Philipps-Universität Marburg
Zitieren
APA
Klein, N., Sanchez-Londono, M., Kara, M. M., Gomes-Filho, J. V., Novak, S., Kholeif, K. H., Pekarek, L., Caliskan, N., & Randau, L. (2025). Type I-Fv and engineered type IV-A1 CRISPR–Cas effectors facilitate genome reduction in Escherichia coli. Nucleic Acids Research, 53(22). https://doi.org/10.1093/nar/gkaf1399
Vancouver
Klein N, Sanchez-Londono M, Kara MM, Gomes-Filho JV, Novak S, Kholeif KH, et al. Type I-Fv and engineered type IV-A1 CRISPR–Cas effectors facilitate genome reduction in Escherichia coli. Nucleic Acids Research. 2025;53(22). doi:10.1093/nar/gkaf1399
BibTeX
@article{Klein2025,
author = {Klein, Nathalie and Sanchez-Londono, Mariana and Kara, Meral M and Gomes-Filho, José Vicente and Novak, Samuel and Kholeif, Karim H and Pekarek, Lukas and Caliskan, Neva and Randau, Lennart},
title = {Type I-Fv and engineered type IV-A1 CRISPR–Cas effectors facilitate genome reduction in Escherichia coli},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {22},
doi = {10.1093/nar/gkaf1399}
}
EUVIMED